蛋白S抗体作为B型血友病的辅助疗法
Hope P Wilson1,2, Aliyah Pierre1, Ashley L Paysse1
1Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, New Orleans, LA.
Blood advances
|September 29, 2023
概括
通过抗体抑制蛋白S (PS) 显著提高了因子IX (FIX) 替代疗法对血友病B (HB) 的有效性. 这种方法延长了FIX活性,改善了严重HB患者的血栓生成和纤维素积累.
科学领域:
- 血液学 血液学 血液学
- 凝血科学 凝血科学
- 药理学 药理学是指药理学的学科.
背景情况:
- 血友病B (HB) 是由遗传的因子IX (FIX) 缺乏症引起的,在儿科患者中经常严重.
- 目前的FIX替代疗法由于FIX的半衰期短以及由蛋白S (PS) 的抑制,其持续时间有限.
- 通过抑制激活FIX (FIXa),影响血栓形成,PS自然限制凝血.
研究的目的:
- 调查抑制PS是否可以延长FIX的功能半衰期.
- 评估PS抗体作为B型血友病的辅助疗法的疗效.
主要方法:
- 测定血中的凝血时间和血栓生成,有或没有PS抗体.
- 包括11名没有并发症的儿科HB患者.
- 使用FIX±PS抗体在B型血友病小鼠中的体内血栓形成评估.
主要成果:
- 一个PS抗体加速了凝血,并显著增加了峰值血栓生成.
- 即使在严重的HB患者的血中也观察到增强的FIX活性.
- 用FIX和PS抗体治疗的B型血友病小鼠显示纤维素积累4.5倍.
结论:
- 用抗体抑制PS可增强FIX活性,并延长其治疗效果.
- 一种PS抗体是对轻度,中度和重度血友病B的有前途的辅助疗法.
- 这一策略可以改善儿科HB患者的FIX替代疗法结果.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
741
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
741
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
203
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
203
Disorders of Hemostasis
982
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
982
Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16


